RCVS: The Rational Approach to Diagnosis and Treatment

Withdrawn before enrolling · Phase 4

Conditions studied: Reversible Cerebral Vasoconstriction Syndrome

In brief

This is a randomized clinical trial of short-acting nimodipine versus twice daily extended release verapamil to treat patients presenting with Reversible Cerebral Vasoconstriction Syndrome (RCVS).

Key facts

Study ID

NCT03150524

Run by

Johns Hopkins University

People needed

0

Starts

2017-07-01

Expected to finish

2019-05-31

Last updated by the study team

2019-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Johns Hopkins Bayview Medical Center — Baltimore, Maryland, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.